Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Rituximab 17Cyclophosphamide 9fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6Filgrastim 6Mycophenolic Acid 5ibritumomab tiuxetan 4Whole-Body Irradiation 4Indium 4Everolimus 4Bortezomib 4romidepsin 3Sirolimus 3Etoposide 3Cyclosporine 3temsirolimus 2bazlitoran 2alvocidib 2Tacrolimus 2Radiotherapy 2Prednisone 2Methotrexate 2In Situ Hybridization, Fluorescence 2Ifosfamide 2Gene Expression Profiling 2Carboplatin 2Busulfan 2Biopsy 2Antilymphocyte Serum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Waldenstrom Macroglobulinemia × veltuzumab × Clear all
NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡